LRS chambers occupy an odd position in cell sourcing. They are a by-product that turned out to be useful, they are cheap relative to what they contain, and they are almost never explained anywhere a buyer would look. The result is that people either rely on them without understanding their limits or dismiss them without realising what they offer.
What they are
LRS stands for leukoreduction system. During platelet apheresis, a chamber in the collection set traps leukocytes to keep them out of the platelet product, since leukocytes in a transfused product cause problems. That chamber is a waste component from the transfusion perspective.
From a research perspective it is a small, concentrated collection of leukocytes from a single donor, obtained without any additional procedure and without any additional burden on the donor.
What they give you
| LRS chamber | Leukopak | |
|---|---|---|
| Origin | By-product of platelet apheresis | Purpose-run leukapheresis |
| Leukocyte content | Modest, but concentrated for its volume | Substantially higher |
| Volume | Small | Larger |
| Cost per unit | Low | Higher |
| Donor selection | Constrained by who happened to donate platelets | Can be scheduled to criteria, subject to availability |
| Repeat from same donor | Only if that donor gives platelets again | Documented recall program where the supplier owns collection |
| Suits | Method development, screening, teaching | Cell therapy development, large-scale isolation, continuity |
Related product
Leukopak formats. Single-donor starting material, fresh or cryopreserved, with full donor documentation.
Where they are genuinely good
For method development they are close to ideal. The cells are fresh, single-donor and inexpensive, which makes them well suited to optimising an isolation protocol or troubleshooting an assay before committing to material that costs considerably more.
They are also useful for screening across many donors, since the low unit cost makes breadth affordable in a way that larger collections do not.
Where they run out
Cell numbers are the obvious ceiling. Any workflow requiring large quantities from one donor, or requiring a rare population isolated from a large starting pool, will exhaust what a chamber contains.
The subtler limitation is donor selection. LRS chambers come from whoever happened to donate platelets, which means selecting donors on genotype or characteristics is either impossible or dependent on the collecting organization having characterized them for other reasons. Programs that need HLA-defined donors, or need to return to the same donor later, are asking for something a by-product supply chain is not built to deliver.
Handling considerations
Chambers are small and the cells are concentrated, so flushing the chamber thoroughly matters more than it does with a larger volume where a small residual loss is proportionally trivial. Platelet carryover is typically higher than in a purpose-run collection, given what the device was collecting when the leukocytes were trapped, so preparations often need additional platelet removal.
Where they sit alongside other sources
The comparison against buffy coats and whole blood is covered in buffy coat versus leukopak versus whole blood. Broadly, LRS chambers and buffy coats occupy adjacent positions as inexpensive by-product sources suited to development work, while purpose-run leukopaks occupy the position where donor definition and scale matter. OrganaBio documents leukopaks at a minimum of 10 billion cells per single-donor unit with characterization applied at donor program level and a repeat-collection program for eligible donors.
Frequently asked questions
What is an LRS chamber?
LRS stands for leukoreduction system. During platelet apheresis a chamber in the collection set traps leukocytes to keep them out of the platelet product. From a transfusion perspective it is waste; from a research perspective it is a small concentrated single-donor leukocyte collection.
How do LRS chambers compare with leukopaks?
A leukopak comes from a purpose-run leukapheresis and contains substantially more leukocytes, can be scheduled to donor criteria, and supports repeat collection. An LRS chamber is a cheaper by-product with modest cell numbers and donor selection constrained by who happened to donate platelets.
What are LRS chambers good for?
Method development, protocol optimisation, assay troubleshooting and screening across many donors, where fresh single-donor cells at low unit cost matter more than large numbers or defined donors.
What are the limitations of LRS chambers?
Cell numbers cap what you can do from one donor, and donor selection is largely impossible because the material comes from whoever donated platelets. Programs needing HLA-defined donors or the ability to return to the same donor are asking for something a by-product supply chain cannot provide.
Do LRS chambers need special handling?
Flushing the chamber thoroughly matters more than with larger volumes, since a small residual loss is proportionally significant. Platelet carryover is typically higher than in a purpose-run collection, so preparations often need additional platelet removal.
Can I use LRS chambers for cell therapy development?
For early development and process optimisation, yes. For work requiring defined donors, large cell numbers or continuity across a program, a purpose-run collection is the appropriate source.
Is it inconsistent to use LRS chambers then switch to leukopaks?
No, it is a sensible progression. Using an inexpensive by-product source to work out how to do something and then moving to a purpose-run collection to do it at scale with defined donors is a reasonable sequence.
Talk to OrganaBio
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
